{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:39:35Z","timestamp":1792460375489,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002597","name":"Kyung Hee University","doi-asserted-by":"publisher","award":["KHU-20242590"],"award-info":[{"award-number":["KHU-20242590"]}],"id":[{"id":"10.13039\/501100002597","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1F1A1063638"],"award-info":[{"award-number":["2022R1F1A1063638"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1I1A2054560"],"award-info":[{"award-number":["NRF-2021R1I1A2054560"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10495-026-02340-z","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:32:52Z","timestamp":1777419172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Celecoxib potentiates ribociclib-induced apoptosis and anti-tumor activity by co-targeting COX-2\/NF-\u03baB and PI3K\/AKT\/mTOR pathways in hormone receptor-positive\/HER2-negative breast cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Sanghee","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hail","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minji","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumin","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-5777","authenticated-orcid":false,"given":"Seok-Geun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2340_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"2340_CR2","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/j.clbc.2020.01.014","volume":"20","author":"A Thomas","year":"2020","unstructured":"Thomas A, Rhoads A, Suhl J et al (2020) Incidence and survival by human epidermal growth factor receptor 2 status in young women with stage I-III breast cancer: SEER, 2010\u20132016. Clin Breast Cancer 20:e410\u2013e422","journal-title":"Clin Breast Cancer"},{"key":"2340_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.643956","volume":"11","author":"H Zhao","year":"2021","unstructured":"Zhao H, Gong Y (2021) The prognosis of single hormone receptor-positive breast cancer stratified by HER2 status. Front Oncol 11:643956","journal-title":"Front Oncol"},{"key":"2340_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S1470-2045(20)30534-9","volume":"22","author":"M Toi","year":"2021","unstructured":"Toi M, Imoto S, Ishida T et al (2021) Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22:74\u201384","journal-title":"Lancet Oncol"},{"key":"2340_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12282-024-01566-6","volume":"31","author":"Y Yamamoto","year":"2024","unstructured":"Yamamoto Y, Yamauchi C, Toyama T et al (2024) The Japanese breast cancer society clinical practice guidelines for breast cancer, 2022 edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast Cancer 31:340\u2013346","journal-title":"Breast Cancer"},{"key":"2340_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","volume":"31","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M (2024) Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther 31:1283\u20131291","journal-title":"Cancer Gene Ther"},{"key":"2340_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC (2016) Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol 13:417\u2013430","journal-title":"Nat Rev Clin Oncol"},{"key":"2340_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.5455\/medarh.2022.76.333-342","volume":"76","author":"D Hermansyah","year":"2022","unstructured":"Hermansyah D, Firsty NN, Alhudawy MN, Nasution RA (2022) The combination of CDK 4\/6 inhibitors plus endocrine treatment versus endocrine treatment alone in hormone-receptor (HR)-positive breast cancer: a systematic review and meta-analysis. Med Arch 76:333\u2013342","journal-title":"Med Arch"},{"key":"2340_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-020-05755-7","volume":"183","author":"RS Finn","year":"2020","unstructured":"Finn RS, Boer K, Bondarenko I et al (2020) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+\/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat 183:419\u2013428","journal-title":"Breast Cancer Res Treat"},{"key":"2340_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J et al (2023) Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 24:77\u201390","journal-title":"Lancet Oncol"},{"key":"2340_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im SA, Lu YS, Bardia A et al (2019) Overall survival with Ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381:307\u2013316","journal-title":"N Engl J Med"},{"key":"2340_CR12","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","volume":"28","author":"YS Lu","year":"2022","unstructured":"Lu YS, Im SA, Colleoni M et al (2022) Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy Alone in Pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res 28:851\u2013859","journal-title":"Clin Cancer Res"},{"key":"2340_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","volume":"3","author":"ES Knudsen","year":"2017","unstructured":"Knudsen ES, Witkiewicz AK (2017) The strange case of CDK4\/6 inhibitors: mechanisms, resistance, and combination strategies. Trends Cancer 3:39\u201355","journal-title":"Trends Cancer"},{"key":"2340_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119346","volume":"1869","author":"MC Papadimitriou","year":"2022","unstructured":"Papadimitriou MC, Pazaiti A, Iliakopoulos K, Markouli M, Michalaki V, Papadimitriou CA (2022) Resistance to CDK4\/6 inhibition: mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer. Biochim Biophys Acta Mol Cell Res 1869:119346","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2340_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113198","volume":"42","author":"S Kim","year":"2023","unstructured":"Kim S, Armand J, Safonov A et al (2023) Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer. Cell Rep 42:113198","journal-title":"Cell Rep"},{"key":"2340_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00360-5","volume":"7","author":"MM Abu-Khalaf","year":"2023","unstructured":"Abu-Khalaf MM, Alex Hodge K, Hatzis C et al (2023) AKT\/mTOR signaling modulates resistance to endocrine therapy and CDK4\/6 inhibition in metastatic breast cancers. npj Precis Oncol 7:18","journal-title":"npj Precis Oncol"},{"key":"2340_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01510-6","volume":"24","author":"AC Watt","year":"2022","unstructured":"Watt AC, Goel S (2022) Cellular mechanisms underlying response and resistance to CDK4\/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Res 24:17","journal-title":"Breast Cancer Res"},{"key":"2340_CR18","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41598-023-29425-y","volume":"13","author":"MJ Rodriguez","year":"2023","unstructured":"Rodriguez MJ, Perrone MC, Riggio M et al (2023) Targeting mTOR to overcome resistance to hormone and CDK4\/6 inhibitors in ER-positive breast cancer models. Sci Rep 13:2710","journal-title":"Sci Rep"},{"key":"2340_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","volume":"57","author":"A Shanabag","year":"2025","unstructured":"Shanabag A, Armand J, Son E, Yang HW (2025) Targeting CDK4\/6 in breast cancer. Exp Mol Med 57:312\u2013322","journal-title":"Exp Mol Med"},{"key":"2340_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.seminoncol.2024.01.002","volume":"50","author":"D Wekking","year":"2023","unstructured":"Wekking D, Lambertini M, Dessi M et al (2023) CDK4\/6 inhibitors in the treatment of metastatic breast cancer: focus on toxicity and safety. Semin Oncol 50:131\u2013139","journal-title":"Semin Oncol"},{"key":"2340_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53151-8","volume":"14","author":"C Kappel","year":"2024","unstructured":"Kappel C, Elliott MJ, Kumar V, Nadler MB, Desnoyers A, Amir E (2024) Comparative overall survival of CDK4\/6 inhibitors in combination with endocrine therapy in advanced breast cancer. Sci Rep 14:3129","journal-title":"Sci Rep"},{"key":"2340_CR22","doi-asserted-by":"publisher","DOI":"10.1039\/d5md00196j","author":"AE Kassab","year":"2025","unstructured":"Kassab AE (2025) Recent advances in targeting COX-2 for cancer therapy: a review. RSC Med Chem. https:\/\/doi.org\/10.1039\/d5md00196j","journal-title":"RSC Med Chem"},{"key":"2340_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1596","volume":"15","author":"A Sahu","year":"2023","unstructured":"Sahu A, Raza K, Pradhan D, Jain AK, Verma S (2023) Cyclooxygenase-2 as a therapeutic target against human breast cancer: a comprehensive review. WIREs Mech Dis 15:e1596","journal-title":"WIREs Mech Dis"},{"key":"2340_CR24","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.1210\/endo.137.12.8940410","volume":"137","author":"Y Zhao","year":"1996","unstructured":"Zhao Y, Agarwal VR, Mendelson CR, Simpson ER (1996) Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739\u20135742","journal-title":"Endocrinology"},{"key":"2340_CR25","first-page":"6096","volume":"63","author":"RE Harris","year":"2003","unstructured":"Harris RE, Chlebowski RT, Jackson RD et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women\u2019s Health Initiative. Cancer Res 63:6096\u20136101","journal-title":"Cancer Res"},{"key":"2340_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958308","volume":"12","author":"RE Harris","year":"2022","unstructured":"Harris RE, Schwartzbaum JA (2022) Celecoxib may be a viable treatment option for breast cancer patients not treated with chemotherapy. Front Oncol 12:958308","journal-title":"Front Oncol"},{"key":"2340_CR27","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1001\/jamaoncol.2021.2193","volume":"7","author":"RC Coombes","year":"2021","unstructured":"Coombes RC, Tovey H, Kilburn L et al (2021) Effect of celecoxib vs Placebo as adjuvant therapy on disease-free survival among Patients with breast cancer: the REACT randomized clinical trial. JAMA Oncol 7:1291\u20131301","journal-title":"JAMA Oncol"},{"key":"2340_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","volume":"10","author":"RM Neve","year":"2006","unstructured":"Neve RM, Chin K, Fridlyand J et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515\u2013527","journal-title":"Cancer Cell"},{"key":"2340_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117930","volume":"184","author":"S Han","year":"2025","unstructured":"Han S, Yi YW, Kim H et al (2025) Structure-activity relationship analysis of mono-methylated quercetins by comprehensive MS\/MS analysis and anti-proliferative efficacy in human colorectal cancer cells. Biomed Pharmacother 184:117930","journal-title":"Biomed Pharmacother"},{"key":"2340_CR30","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440\u2013446","journal-title":"Cancer Res"},{"key":"2340_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133122","author":"Y Yoo","year":"2021","unstructured":"Yoo Y, Park SY, Jo EB et al (2021) Overexpression of replication-dependent histone signifies a subset of dedifferentiated liposarcoma with increased aggressiveness. Cancers. https:\/\/doi.org\/10.3390\/cancers13133122","journal-title":"Cancers"},{"key":"2340_CR32","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.3390\/cancers14215215","volume":"14","author":"YW Yi","year":"2022","unstructured":"Yi YW, You KS, Han S et al (2022) Inhibition of IkappaB kinase is a potential therapeutic strategy to circumvent resistance to epidermal growth factor receptor inhibition in triple-negative breast cancer cells. Cancers 14:5215","journal-title":"Cancers"},{"key":"2340_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117362","volume":"319","author":"S Han","year":"2024","unstructured":"Han S, Lim SL, Kim H et al (2024) Ethyl acetate fraction of Osmanthus fragrans var. aurantiacus and its triterpenoids suppress proliferation and survival of colorectal cancer cells by inhibiting NF-kappaB and COX2. J Ethnopharmacol 319:117362","journal-title":"J Ethnopharmacol"},{"key":"2340_CR34","doi-asserted-by":"publisher","first-page":"14826","DOI":"10.3390\/ijms232314826","volume":"23","author":"S Han","year":"2022","unstructured":"Han S, Kim H, Lee MY et al (2022) Anti-cancer effects of a new herbal medicine PSY by inhibiting the STAT3 signaling pathway in colorectal cancer cells and Its phytochemical analysis. Int J Mol Sci 23:14826","journal-title":"Int J Mol Sci"},{"key":"2340_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mocell.2024.100141","volume":"47","author":"D Bong","year":"2024","unstructured":"Bong D, Sohn J, Lee SV (2024) Brief guide to RT-qPCR. Mol Cells 47:100141","journal-title":"Mol Cells"},{"key":"2340_CR36","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00429-023-02676-1","volume":"228","author":"H Kim","year":"2023","unstructured":"Kim H, Choi M, Han S et al (2023) Expression patterns of AEG-1 in the normal brain. Brain Struct Funct 228:1629\u20131641","journal-title":"Brain Struct Funct"},{"key":"2340_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.mocell.2024.100157","volume":"48","author":"G Park","year":"2025","unstructured":"Park G, Kim SS, Shim J, Lee SV (2025) Brief guide to immunostaining. Mol Cells 48:100157","journal-title":"Mol Cells"},{"key":"2340_CR38","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.2147\/CMAR.S178567","volume":"10","author":"J Li","year":"2018","unstructured":"Li J, Hao Q, Cao W, Vadgama JV, Wu Y (2018) Celecoxib in breast cancer prevention and therapy. Cancer Manag Res 10:4653\u20134667","journal-title":"Cancer Manag Res"},{"key":"2340_CR39","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s11095-023-03571-4","volume":"40","author":"U Bak","year":"2023","unstructured":"Bak U, Krupa A (2023) Challenges and opportunities for celecoxib repurposing. Pharm Res 40:2329\u20132345","journal-title":"Pharm Res"},{"key":"2340_CR40","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41416-024-02852-y","volume":"131","author":"D Prasad","year":"2024","unstructured":"Prasad D, Baldelli E, Blais EM et al (2024) Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort. Br J Cancer 131:1543\u20131554","journal-title":"Br J Cancer"},{"key":"2340_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02288-z","volume":"41","author":"DME Alian","year":"2024","unstructured":"Alian DME, Helmy MW, Haroun M, Moussa N (2024) Modulation of autophagy and apoptosis can contribute to the anticancer effect of Abemaciclib\/Celecoxib combination in colon cancer cells. Med Oncol 41:43","journal-title":"Med Oncol"},{"key":"2340_CR42","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1158\/0008-5472.CAN-03-1086","volume":"64","author":"C Han","year":"2004","unstructured":"Han C, Leng J, Demetris AJ, Wu T (2004) Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1\/cip1 and p27kip1 and cell cycle arrest. Cancer Res 64:1369\u20131376","journal-title":"Cancer Res"},{"key":"2340_CR43","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.clinthera.2014.06.015","volume":"36","author":"J Chen","year":"2014","unstructured":"Chen J, Shen P, Zhang XC, Zhao MD, Zhang XG, Yang L (2014) Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin Ther 36:1253\u20131263","journal-title":"Clin Ther"},{"key":"2340_CR44","doi-asserted-by":"crossref","unstructured":"Tive L (2000) Celecoxib clinical profile. Rheumatology (Oxford) 39 Suppl 2:21\u201328; discussion 57\u201329","DOI":"10.1093\/rheumatology\/39.suppl_2.21"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02340-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02340-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02340-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:58:37Z","timestamp":1779281917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02340-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2340"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02340-z","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"132"}}